Non-enzymatic single-molecule immune reaction detection method
Through the method of fully encapsulating magnetic beads by droplets, combined with optical signals to enhance nanoparticles, the problems of complex detection system and poor stability in single-molecular immunoassay technology are solved, high sensitivity detection for low-concentration proteins is achieved, and the detection instrument is optimized stability and cost-effectiveness.
Patent Information
- Application Number
- CN202411391231.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-12-18
- Filing Date
- 2024-09-30
- Publication Date
- 2024-11-29
AI Technical Summary
The existing single-molecule immunoassay technology has problems such as complex detection system, high requirements for equipment precision, poor stability of detection reagents, difficult cost control, and inability to be well applied to protein detection, which hinders its application in the scientific research and medical diagnosis markets.
The magnetic beads are fully encapsulated by droplets, and the capture antibody is bound to the first site of the target molecule, and then the optical signal-enhancing nanoparticles are bound to the second site of the target molecule through the conjugate, and the droplets are encapsulated and dispersed. , collect and analyze optical signals to improve detection sensitivity and stability.
Significantly improve the sensitivity and correlation between sample concentration and fluorescence intensity of the detection project, optimize the stability of the detection instrument, reduce background noise and signal scattering, realize the detection of very low concentration proteins, reduce sample usage and matrix effects , improves the reliability and cost-effectiveness of testing.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
[0001] This application claims the priority of the Chinese patent application filed with the China Patent Office on December 18, 2023, with application number 202311760709.7 and invention name “A non-enzymatic single molecule immune reaction detection method”, the entire contents of which are incorporated by reference in this application. Technical Field
[0002] The invention relates to the field of biotechnology, and in particular to a non-enzymatic single molecule immune reaction detection method. Background Art
[0003] At present, clinical detection methods mainly include chemiluminescence analysis (CLIA) and enzyme linked immunosorbent assay (ELISA). The luminescence process of CLIA is short, the background of fluorescence is high, and there is a problem of low detection accuracy. ELISA requires manual sample addition and plate washing, which is time-consuming and is affected by different operator techniques, and the experimental results are also different. In addition, CLIA and ELISA are quantitatively measured based on the relationship between signal intensity and target concentration. The higher the intensity, the higher the concentration of the target being measured. This detection method can only achieve a detection level of picograms, and the sensitivity is low. Single-molecule immunity is a new type of immunoassay method based on the theoretical basis of Poisson distribution, and the detection sensitivity can reach the single-molecule level. In the early stages of diseases such as cancer and neurological disorders, the concentration range of related protein markers in serum is 10 -16 M to 10 -12M, but the sensitivity of conventional immunoassay methods (chemiluminescence, colloidal gold, etc.) cannot reach this level. Therefore, single-molecule immunoassay can be applied to the early diagnosis of diseases such as cancer and neurological disorders, medication guidance during treatment, and later disease monitoring. Single-molecule detection counts molecules that can generate signals, which is more visible and digital, ensuring high reproducibility. Quanterix developed the Simoa series of instruments based on protease signal amplification, using a micropore to load a magnetic bead. In the commercialized Simoa HD-1 analyzer, the magnetic beads are loaded and isolated by gravity, but only 5% of the magnetic beads are separated and analyzed. Therefore, it also leads to large repetitive differences, poor reagent stability, high cost and other problems, which is not suitable for large-scale productization and application promotion. In addition, Suzhou Yuce Biotechnology Co., Ltd. uses in situ signal enhancement nanoparticles as signal amplification and has developed corresponding single-molecule immunoassay instruments. However, since Yuce needs to overcome a large resistance to connect the in-situ signal enhancement nanoparticles and magnetic beads through a single protein molecule, or the in-situ signal enhancement nanoparticles and magnetic beads combined by a single protein molecule are easier to disconnect, this leads to poor stability of the detection system and a large coefficient of variation of the test results. It is also difficult to distinguish the number of in-situ signal enhancement nanoparticles bound to the magnetic beads, which narrows the detection range of single-molecule immunoassay.
[0004] The existing single-molecule detection technology has many problems, such as complex detection system, extremely high precision requirements for detection equipment, poor stability of detection reagents, high precision requirements for auxiliary consumables, difficult to control costs, and poor application in protein detection. These problems have greatly hindered the application of single-molecule detection technology in scientific research and medical diagnosis markets. Summary of the invention
[0005] In view of this, the present invention provides a non-enzymatic single-molecule immune reaction detection method, which can significantly improve the sensitivity and correlation between the sample concentration and fluorescence intensity of the detection item by fully wrapping the magnetic beads with droplets, and optimize the stability of the detection instrument.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The present invention provides a non-enzymatic single molecule immune reaction detection method, comprising the following steps:
[0008] Step (1): mixing a sample to be tested with a capture antibody immobilized on a solid phase carrier, incubating, washing, and obtaining a first complex, wherein the capture antibody binds to a first site of a target molecule in the sample;
[0009] Step (2): mixing the detection antibody, the optical signal enhancing nanoparticles and the first complex described in step (1), incubating, washing, and obtaining a second complex, wherein the detection antibody binds to the second site of the target molecule, and the detection antibody is coupled to the optical signal enhancing nanoparticles;
[0010] Step (3): Encapsulating the second complex described in step (2) with droplets, dispersing, collecting optical signals, analyzing, and obtaining detection results.
[0011] In some specific embodiments of the present invention, the optical imaging equipment used for the acquisition in the above-mentioned non-enzymatic single-molecule immune reaction detection method includes a Nikon Eclipse Ti-U fluorescence microscope, other fluorescence microscopes of the Nikon Eclipse Ti series, a Leica DMi8 fluorescence microscope, an Olympus IX series fluorescence microscope, a CIS, a CCD or a CMOS camera.
[0012] In some specific embodiments of the present invention, the solid phase carrier in the above non-enzymatic single molecule immunoreaction detection method is modified with a functional group capable of coupling with an antibody.
[0013] In some specific embodiments of the present invention, the solid phase carrier in the above non-enzymatic single molecule immune reaction detection method comprises one or more of magnetic beads, micrometer-scale microspheres or nanometer-scale microspheres;
[0014] The particle size of the magnetic beads is 1 μm, 1.5 μm, 2 μm, 2.5 μm or 3 μm.
[0015] In some specific embodiments of the present invention, the target molecule in the above-mentioned non-enzymatic single-molecule immune reaction detection method includes one or more of proteins, polysaccharides, small molecules with biological activity, or complexes of small molecules and proteins.
[0016] In some specific embodiments of the present invention, the coupling in the above-mentioned non-enzymatic single-molecule immunoreaction detection method includes direct coupling or indirect coupling;
[0017] The direct coupling includes coupling by physical adsorption or coupling by chemical modification;
[0018] Such indirect coupling includes coupling via a biotin-streptavidin system.
[0019] In some specific embodiments of the present invention, the particle size of the optical signal enhancing nanoparticles in the above-mentioned non-enzymatic single molecule immunoreaction detection method is 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 150 nm, 160 nm, 170 nm, 180 nm, 190 nm, 200 nm, 210 nm, 220 nm, 230 nm, 240 nm, 250 nm, 260 nm, 270 nm, 280 nm, 290 nm or 300 nm.
[0020] In some specific embodiments of the present invention, the luminescent material of the optical signal-enhancing nanoparticles in the above-mentioned non-enzymatic single-molecule immune reaction detection method includes one or more of organic fluorescent dyes, quantum dots, fluorescent proteins, rare earth luminescent materials, aggregation-induced luminescent materials or polymer luminescent materials.
[0021] In some specific embodiments of the present invention, the carrier material of the optical signal enhancing nanoparticles in the above non-enzymatic single molecule immunoreaction detection method includes one or more of polystyrene, silica, dextran, agarose, inorganic metal compounds or polyacrylamide.
[0022] In some specific embodiments of the present invention, the structure of the optical signal enhancing nanoparticles in the above non-enzymatic single molecule immune reaction detection method includes one or more of a hollow structure, a porous structure or a core-shell structure.
[0023] In some specific embodiments of the present invention, the above-mentioned non-enzymatic single molecule immunoreaction detection method comprises:
[0024] The incubation time in step (1) is 15 min, 20 min, 25 min, 30 min, 35 min, 40 min, 45 min, 50 min, 55 min or 60 min; and / or
[0025] The incubation temperature in step (1) is 25°C, 30°C, 35°C or 40°C; and / or
[0026] The incubation time in step (2) is 15 min, 20 min, 25 min, 30 min, 35 min, 40 min, 45 min, 50 min, 55 min or 60 min; and / or
[0027] The incubation temperature in step (2) is 25°C, 30°C, 35°C or 40°C.
[0028] In some specific embodiments of the present invention, the capture antibody in the above non-enzymatic single molecule immune reaction detection method includes one or more of a monoclonal antibody and a polyclonal antibody.
[0029] In some specific embodiments of the present invention, the sources of the capture antibody in the above-mentioned non-enzymatic single-molecule immunoreaction detection method include rat, mouse, rabbit or goat sources.
[0030] In some specific embodiments of the present invention, the capture antibody in the above-mentioned non-enzymatic single-molecule immune reaction detection method is from manufacturers including Medix, Hi-Tide, Ibaxin, Biospacific or Abcam.
[0031] In some specific embodiments of the present invention, the solid phase carrier of the above non-enzymatic single molecule immunoreaction detection method is used to separate and clean the detection sample from the reagent. The capture antibody is fixed on the surface of the solid phase carrier by physical adsorption or chemical modification, and can bind to a binding site of the target molecule to separate it from the sample.
[0032] In some specific embodiments of the present invention, the surface of the solid phase carrier in the above-mentioned non-enzymatic single-molecule immune reaction detection method is modified with active functional groups that can be covalently coupled to antibodies, and the active functional groups include one or more of hydroxyl, carboxyl, amino, thiol, alkene, alkynyl, succinimide ester groups and their derivative groups.
[0033] In some specific embodiments of the present invention, the target molecule of the above-mentioned non-enzymatic single-molecule immune response detection method includes one or more of cellular inflammatory factors, Alzheimer's disease blood biomarkers or myocardial markers;
[0034] The cellular inflammatory factors include IL-6 and / or IL-17;
[0035] The Alzheimer's disease blood biomarkers include one or more of p-tau 181, p-tau 217, p-tau 231, NFL, Aβ-42 or Aβ-40;
[0036] The myocardial markers include cTnI;
[0037] The tumor markers include PSA.
[0038] In some specific embodiments of the present invention, the conjugate of the detection antibody and the optical signal enhancing nanoparticles in the above-mentioned non-enzymatic single-molecule immunoreaction detection method includes direct coupling and indirect coupling, wherein direct coupling refers to the optical signal enhancing nanoparticles directly binding to the detection antibody, that is, the detection antibody is directly adsorbed or coupled to the optical signal enhancing nanoparticles by physical adsorption or chemical modification. Chemical modification refers to the surface modification of the optical signal enhancing nanoparticles with active functional groups that can be covalently coupled to antibodies, such as hydroxyl, carboxyl, amino, succinimidyl ester, sulfonyl (such as toluenesulfonyl) and their derivative groups. One or more. Indirect coupling refers to the specific labeling of the optical signal enhancing nanoparticles on the detection antibody by combining the anti-detection antibody with the biotin-streptavidin system.
[0039] In some specific embodiments of the present invention, the detection antibodies in the above-mentioned non-enzymatic single-molecule immune reaction detection method may include one or more of monoclonal antibodies and polyclonal antibodies according to their specific characteristics; the detection antibodies may include rat source, mouse source, rabbit source, goat source, etc. according to their source; the detection antibody manufacturers include Medix, Haitide, Yibaixin, Biospacific, Abcam, etc.
[0040] In some specific embodiments of the present invention, the selection of the luminescent material used in the optical signal enhancement nanoparticles in the above non-enzymatic single-molecule immunoreaction detection method includes one or more of organic fluorescent dyes, quantum dots, fluorescent proteins, rare earth luminescent materials, aggregation-induced luminescent materials or polymer luminescent materials;
[0041] The organic fluorescent dye includes fluorescein isothiocyanate, coumarin series or rhodamine series, etc.;
[0042] The quantum dots include CdS, CdSe, CdTe or ZnSe;
[0043] The rare earth luminescent material includes an up-conversion luminescent material or a lanthanide element.
[0044] In some specific embodiments of the present invention, the choice of particle carrier material used in the optical signal enhancement nanoparticles described in the above-mentioned non-enzymatic single-molecule immune response detection method includes one or more of polystyrene, silica, dextran, agarose, inorganic metal compounds, polyacrylamide, etc., and can be classified according to the structure as one or more of a hollow structure, a porous structure, a core-shell structure, etc.
[0045] The key to the present invention is that the binding time of the capture antibody to the first site of the target molecule is 15 min, 20 min, 25 min, 30 min, 35 min, 40 min, 45 min, 50 min, 55 min or 60 min, and the binding temperature is 25°C, 30°C, 35°C or 40°C; the binding time of the detection antibody to the second site of the target molecule is 15 min, 20 min, 25 min, 30 min, 35 min, 40 min, 45 min, 50 min, 55 min or 60 min, and the binding temperature is 25°C, 30°C, 35°C or 40°C.
[0046] The key to the present invention is that in the one-step method, the binding time between the target molecule and the antibody is 15 min, 20 min, 25 min, 30 min, 35 min, 40 min, 45 min, 50 min, 55 min or 60 min, and the reaction time temperature is 25°C, 30°C, 35°C or 40°C.
[0047] In some specific embodiments of the present invention, the above-mentioned non-enzymatic single-molecule immune reaction detection method further comprises: fixing the capture antibody to a solid phase carrier, utilizing the capture antibody to bind to the first site of the target molecule, thereby capturing the target molecule in the sample; simultaneously adding a conjugate of a detection antibody and an optical signal enhancing nanoparticle, and allowing the detection antibody to bind to the second site of the target molecule; (one-step method)
[0048] Encapsulating and dispersing the immune complexes with droplets;
[0049] detecting the optical signal emitted by the fluorescent microspheres using an optical imaging device;
[0050] The number of optical signal-enhancing nanoparticles is counted, and the concentration information of the target molecules in the sample is further calculated;
[0051] The optical imaging equipment includes a Nikon Eclipse Ti-U fluorescence microscope, other fluorescence microscopes of the Nikon Eclipse Ti series, a Leica DMi8 fluorescence microscope, an Olympus IX series fluorescence microscope, a CIS, a CCD or a CMOS camera.
[0052] The non-enzymatic single molecule immune reaction detection method of the present invention has the following effects:
[0053] The number of magnetic beads used in the present invention is 100,000, and all of them are wrapped by droplets, which can not only solve the problem of unstable loading efficiency caused by the magnetic beads falling into the hole, but also reduce background noise and signal scattering, so that the detection sensitivity of the present invention is more than 1,000 times higher than that of the existing conventional ELISA method on average, and very low concentrations of proteins can be detected, and the required sample content is small, which can save precious samples and reduce matrix effects. In the present invention, the magnetic beads are fully loaded, which ensures the stability of the number of magnetic beads and reduces the difference between repetitions. BRIEF DESCRIPTION OF THE DRAWINGS
[0054] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.
[0055] Figure 1 The fluorescence image result of single molecule immunoassay of IL-6 in Example 1 is shown;
[0056] Figure 2 The linear graph of IL-6 detected by single molecule immunoassay in Example 1 is shown;
[0057] Figure 3 The fluorescence image result of single molecule immunoassay of pTau-181 in Example 2 is shown;
[0058] Figure 4 The linear graph of single molecule immunoassay pTau-181 in Example 2 is shown;
[0059] Figure 5 The results of the single molecule immunoassay for IL-6 fluorescence are shown in FIG.
[0060] Figure 6 The linear graph of IL-6 detected by single molecule immunoassay in comparative example is shown. DETAILED DESCRIPTION
[0061] The present invention discloses a non-enzymatic single molecule immune reaction detection method. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0062] The present invention can significantly improve the correlation between the sample concentration and the fluorescence intensity of the detection item by fully encapsulating the magnetic beads with droplets, and optimize the stability of the detection instrument. Specifically, it includes the following steps:
[0063] 1. Fix the capture antibody to the solid phase carrier, add the target molecule, and use the capture antibody to bind to the first site of the target molecule to capture the target molecule in the sample; incubate at a certain temperature and wash;
[0064] 2. Then add the conjugate of detection antibody and optical signal enhancing nanoparticles, and the detection antibody binds to the second site of the target molecule; after incubation at a certain temperature, wash;
[0065] 3. Passing the immune complex formed in the above reaction into a droplet generation chip device to encapsulate and disperse it;
[0066] 4. Detect the optical signal emitted by the optical signal enhancing nanoparticles using an optical imaging device;
[0067] 5. Count the number of optical signal-enhancing nanoparticles and further calculate the concentration information of the target molecules in the sample.
[0068] The key to the present invention lies in the selection of solid phase carriers, which include magnetic beads, micron-scale microspheres and nano-scale microspheres, etc., wherein the magnetic beads include conventional particle sizes of 1 μm, 2 μm, 3 μm, etc.
[0069] The key to the present invention lies in the selection of capture antibodies. Antibodies can be classified according to their specific characteristics and include one or more of monoclonal antibodies and polyclonal antibodies. Antibodies can be classified according to their sources and include rat, mouse, rabbit, goat, etc. Antibody manufacturers include Medix, Hi-Tide, Ibaxin, Biospacific, Abcam, etc.
[0070] The key to the present invention is that the solid phase carrier is used for separation and cleaning of detection samples and reagents. The capture antibody is fixed on the surface of the solid phase carrier by physical adsorption or chemical modification, and can bind to a binding site of the target molecule to separate it from the sample.
[0071] The key to the present invention is that the surface of the solid phase carrier is modified with active functional groups that can be covalently coupled to antibodies, including one or more of hydroxyl, carboxyl, amino, thiol, alkene, alkynyl, succinimide ester groups and their derivative groups.
[0072] The key to the present invention lies in the selection of target molecules, including one or more of proteins, polysaccharides, small molecules with biological activity, or complexes of small molecules and proteins. It is more suitable for low-abundance target molecules, such as cellular inflammatory factors IL-6, IL-17, Alzheimer's blood biomarkers p-tau 181, p-tau 217, p-tau 231, NFL, Aβ-42, Aβ-40, myocardial marker cTnI, tumor marker PSA, etc.
[0073] The conjugate of the detection antibody and the optical signal enhancing nanoparticles of the present invention includes direct coupling and indirect coupling modes, wherein direct coupling refers to the direct binding of the optical signal enhancing nanoparticles to the detection antibody, that is, the detection antibody is directly adsorbed or coupled to the optical signal enhancing nanoparticles by physical adsorption or chemical modification. Chemical modification refers to the surface modification of the optical signal enhancing nanoparticles with active functional groups that can be covalently coupled to the antibody, such as one or more of hydroxyl, carboxyl, amino, succinimidyl ester, sulfonyl (such as toluenesulfonyl) and their derivative groups. Indirect coupling refers to the specific labeling of the optical signal enhancing nanoparticles on the detection antibody by combining the anti-detection antibody with the biotin-streptavidin system.
[0074] The key to the present invention lies in the selection of detection antibodies. Antibodies can be classified according to their specific characteristics and include one or more of monoclonal antibodies and polyclonal antibodies. Antibodies can be classified according to their sources and include rat, mouse, rabbit, goat, etc. Antibody manufacturers include Medix, Hi-Tide, Ibaxin, Biospacific, Abcam, etc.
[0075] The key to the present invention lies in the selection of luminescent materials used in optical signal enhancement nanoparticles, including one or more of organic fluorescent dyes (such as fluorescein isothiocyanate, coumarin series, rhodamine series, etc.), quantum dots (such as CdS, CdSe, CdTe, ZnSe), fluorescent proteins, rare earth luminescent materials (such as up-conversion luminescent materials, lanthanide elements), aggregation-induced luminescent materials, and polymer luminescent materials.
[0076] The key to the present invention lies in the selection of the particle size of the optical signal enhancing nanoparticles. The particle size of the optical signal enhancing nanoparticles is between 100 nm and 300 nm, including the conventionally used particle sizes of 150 nm, 180 nm, 200 nm, 250 nm, 300 nm, etc.
[0077] The key to the present invention lies in the selection of particle carrier materials used in optical signal enhancing nanoparticles, including one or more of polystyrene, silica, dextran, agarose, inorganic metal compounds, polyacrylamide, etc., which can be classified into one or more of hollow structure, porous structure and core-shell structure according to the structure.
[0078] The key to the present invention is that the binding time of the capture antibody to the first site of the target molecule is between 15 and 30 minutes, and the binding temperature is between 25°C and 40°C; the binding time of the detection antibody to the second site of the target molecule is between 15 and 30 minutes, and the binding temperature is between 25°C and 40°C.
[0079] The key to the present invention is that in the one-step method, the binding time between the target molecule and the antibody is 15 min to 1 h, and the reaction time temperature is between 25°C and 40°C.
[0080] The key to the present invention is to use droplets to encapsulate and disperse the magnetic bead immune complex. It should be understood that the expression "one or more of..." includes each object described after the expression and various different combinations of two or more of the described objects, unless otherwise understood from the context and usage. The expression "and / or" combined with three or more described objects should be understood to have the same meaning, unless otherwise understood from the context.
[0081] The use of the terms "comprising", "having" or "containing", including their grammatical synonyms, should generally be understood as open and non-restrictive, for example not excluding other unrecited elements or steps, unless otherwise specifically stated or otherwise understood from the context.
[0082] It should be understood that the order of steps or the order in which certain actions are performed is not important as long as the present invention remains operable. In addition, two or more steps or actions may be performed simultaneously.
[0083] The use of any and all examples or exemplary language, such as "for example" or "including", herein is intended only to better illustrate the invention and does not limit the scope of the invention unless otherwise claimed. No language in this specification should be construed as indicating that any non-claimed element is essential to the practice of the invention.
[0084] In addition, the numerical ranges and parameters used to define the present invention are approximate values, and the relevant values in the specific embodiments have been presented as accurately as possible. However, any numerical value inherently inevitably contains standard deviations due to individual test methods. Therefore, unless otherwise expressly stated, it should be understood that all ranges, quantities, values and percentages used in this disclosure are modified by "about". Here, "about" generally means that the actual value is within plus or minus 10%, 5%, 1% or 0.5% of a specific value or range.
[0085] Unless otherwise specified, the raw materials, reagents, consumables and instruments involved in the present invention are all common commercial products and can be purchased from the market.
[0086] The present invention will be further described below in conjunction with embodiments:
[0087] Example 1: IL-6 single molecule immune response detection
[0088] 1. Magnetic beads modified with antibodies:
[0089] 1) Take 16.7 μL of 30 mg / mL Dynabeads M-270 carboxylic acid magnetic beads (Thermo M270) and place them in a 2 mL centrifuge tube. Mix well and place on a magnetic separator for 1 min. Discard the supernatant.
[0090] 2) Add 300 μL of magnetic bead diluent (10 mM PBS containing 0.1% TW20, pH = 7.4), vortex to mix, place on a magnetic separator for 1 min, discard the supernatant, and repeat the above washing operation 3 times;
[0091] 3) Add 300 μL magnetic bead coupling buffer (50 mM MES, pH 5.0), vortex to mix, place on a magnetic separator for 1 min, and discard the supernatant;
[0092] 4) Add 291 μL of magnetic bead coupling buffer, vortex to mix, then add 9 μL of 10 mg / mL EDC, vortex to mix, and shake at 2-8°C for 30 min;
[0093] 5) Place the magnetic bead solution on a magnetic bead separator for 1 min, discard the supernatant, add 300 μL of magnetic bead coupling buffer, vortex to mix, place on a magnetic separator for 15 s, and discard the supernatant;
[0094] 6) Quickly add 300 μL IL-6 capture antibody (Abcam Anti-IL-6 antibody, ab9324), vortex to mix, and shake at 2-8°C for 2 h;
[0095] 7) Place the magnetic bead solution on a magnetic bead separator for 1 min, discard the supernatant, add 300 μL of magnetic bead washing solution, vortex to mix, place on a magnetic separator for 1 min, and discard the supernatant;
[0096] 8) Add 300 μL magnetic bead blocking solution (purchased from Bio-Tech, catalog number: P0220), vortex to mix, and shake at room temperature for 45 minutes;
[0097] 9) Place the magnetic bead solution on a magnetic bead separator for 1 min, discard the supernatant, add 300 μL of magnetic bead diluent, vortex to mix, place on a magnetic separator for 1 min, discard the supernatant, and repeat the above washing operation 3 times;
[0098] 10) Add 300 μL of magnetic bead diluent, vortex to mix, place on a magnetic separator for 1 min, and discard the supernatant;
[0099] 11) Add 300 μL magnetic bead storage solution (10 mM PBS containing 0.1% BSA and 0.1% TW20, pH=7.4), vortex to mix, and store at 2-8°C.
[0100] 2. Optical signal enhancement of nanoparticle-modified antibodies:
[0101] 1) Take 100 μL of 1% optical signal enhancing nanoparticles (purchased from Suzhou Weidu Biotechnology, catalog number: FG0300CA) and place them in a centrifuge, centrifuge for 15 min, and discard the supernatant;
[0102] 2) Add 500 μL of washing solution (10 mM PBS containing 0.1% TW20, pH = 7.4), vortex to mix, centrifuge for 15 minutes, discard the supernatant, and repeat the above washing operation 3 times;
[0103] 3) Add 50 μL of 10 mg / mL EDC and 50 μL of 10 mg / mL NHS and shake at room temperature for 30 min;
[0104] 4) The optical signal enhancement nanoparticle solution was centrifuged for 15 min, the supernatant was discarded, 500 μL of coupling buffer (50 mM MES, pH 5.0) was added, vortexed to mix, centrifuged for 15 min, the supernatant was discarded, and the above operation was repeated 3 times;
[0105] 5) Add 500 μL of coupling buffer and vortex to mix. Add 0.1 mg of IL-6 detection antibody (Abcam biotin Anti-IL-6 antibody, ab84251) and shake at room temperature for 2 h;
[0106] 6) Add 500 μL of coupling buffer, vortex to mix, centrifuge for 15 min, and discard the supernatant;
[0107] 7) Add 500 μL of blocking buffer (purchased from Bio-Tech, catalog number: P0220) and shake at room temperature for 45 min;
[0108] 8) The blocked optical signal enhancing nanoparticle solution was centrifuged for 15 min and the supernatant was discarded;
[0109] 9) Add 500 μL of cleaning solution, vortex to mix, centrifuge for 15 min, and discard the supernatant;
[0110] 10) Add 500 μL of optical signal enhancement nanoparticle storage solution (10 mM PBS containing 0.1% BSA and 0.1% TW20, pH = 7.4), vortex to mix, centrifuge for 15 min, and discard the supernatant;
[0111] 11) Add 500 μL of optical signal enhancement nanoparticle storage solution, vortex to mix, and store at 2-8°C.
[0112] 3. Single molecule immune response detection:
[0113] 1) Preparation of test samples: Use sample diluent (10 mM PBS) to dilute the IL-6 standard sample to 0 pg / mL, 0.01 pg / mL, 0.05 pg / mL, 0.1 pg / mL, 0.5 pg / mL, 1 pg / mL, 5 pg / mL, 10 pg / mL, and 50 pg / mL;
[0114] 2) Take 100 μL of the sample to be tested, add 1 μL of 1.6 mg / mL magnetic bead antibody complex, mix and shake at room temperature for 30 min;
[0115] 3) After the reaction, wash and add 50 μL of optical signal enhancement nanoparticle detection antibody complex, mix and shake at room temperature for 30 min;
[0116] 4) Finally, the immune complex was washed, resuspended in 10 μL of detection solution (10 mM PBS containing 0.1% TW20, pH=7.4), and passed into a droplet generation chip device (purchased from Zhongxin Qiheng, ZX-LD-100Y) to generate droplets encapsulating magnetic beads. The complex was detected under an optical imaging device, Leica DMi8 fluorescence microscope, to obtain a fluorescent image, which was processed and analyzed to obtain the experimental results.
[0117] 4. Experimental Results
[0118] The results showed that the linear range of IL-6 detection in the present invention was 0-50 pg / mL, the lower limit of detection was 0.01 pg / mL, and its R 2 = 0.9999, which meets the requirements. The fluorescence results are as follows Figure 1 As shown, the line graph is Figure 2 shown.
[0119] Example 2: p-Tau 181 single molecule immunoreaction detection
[0120] 1. Magnetic beads modified with antibodies:
[0121] 1) Take 21.9 μL of 25.4 mg / mL Bangs 3.06 μm carboxylated (Bangs 11653) magnetic beads, place in a 2 mL centrifuge tube, mix well, place on a magnetic separator for 1 min, and discard the supernatant;
[0122] 2) Add 300 μL of magnetic bead diluent (10 mM PBS containing 0.1% TW20, pH=7.4), vortex to mix, place on a magnetic separator for 1 min, discard the supernatant, and repeat the above washing operation 3 times;
[0123] 3) Add 300 μL magnetic bead coupling buffer (10 mM MES, pH 5.0), vortex to mix, place on a magnetic separator for 1 min, and discard the supernatant;
[0124] 4) Add 291 μL of magnetic bead coupling buffer, vortex to mix, then add 9 μL of 10 mg / mL EDC, vortex to mix, and shake at 2-8°C for 30 min;
[0125] 5) Place the magnetic bead solution on a magnetic bead separator for 1 min, discard the supernatant, add 300 μL of magnetic bead coupling buffer, vortex to mix, place on a magnetic separator for 15 s, and discard the supernatant;
[0126] 6) Quickly add 300 μL p-Tau 181 capture antibody (Medix, Anti-h p-Tau 181 R13321SPTN-5), vortex to mix, and shake at 2-8°C for 2 h;
[0127] 7) Place the magnetic bead solution on a magnetic bead separator for 1 min, discard the supernatant, add 300 μL of magnetic bead washing solution, vortex to mix, place on a magnetic separator for 1 min, and discard the supernatant;
[0128] 8) Add 300 μL magnetic bead blocking solution (purchased from Bio-Tech, catalog number: P0220), vortex to mix, and shake at room temperature for 45 minutes;
[0129] 9) Place the magnetic bead solution on a magnetic bead separator for 1 min, discard the supernatant, add 300 μL of magnetic bead diluent, vortex to mix, place on a magnetic separator for 1 min, discard the supernatant, and repeat the above washing operation 3 times;
[0130] 10) Add 300 μL of magnetic bead diluent, vortex to mix, place on a magnetic separator for 1 min, and discard the supernatant;
[0131] 11) Add 300 μL magnetic bead storage solution (10 mM PBS containing 0.1% BSA and 0.1% TW20, pH=7.4), vortex to mix, and store at 2-8°C.
[0132] 2. Optical signal enhancement of nanoparticle-modified antibodies:
[0133] 1) Take 100 μL of 1% optical signal enhancing nanoparticles (purchased from Suzhou Weidu Biotechnology, catalog number: FG0300CA) and place them in a centrifuge, centrifuge for 15 min, and discard the supernatant;
[0134] 2) Add 500 μL of washing solution (10 mM PBS containing 0.1% TW20, pH = 7.4), vortex to mix, centrifuge for 15 minutes, discard the supernatant, and repeat the above washing operation 3 times;
[0135] 3) Add 50 μL of 10 mg / mL EDC and 50 μL of 10 mg / mL NHS and shake at room temperature for 30 min;
[0136] 4) The optical signal enhancement nanoparticle solution was centrifuged for 15 min, the supernatant was discarded, 500 μL of coupling buffer (50 mM MES, pH 5.0) was added, vortexed to mix, centrifuged for 15 min, the supernatant was discarded, and the above operation was repeated 3 times;
[0137] 5) Add 500 μL of coupling buffer and vortex to mix. Add 0.1 mg of p-Tau 181 detection antibody (Medix, Anti-h Tau R13301 SPTN-5) and shake at room temperature for 2 h;
[0138] 6) Add 500 μL of coupling buffer, vortex to mix, centrifuge for 15 min, and discard the supernatant;
[0139] 7) Add 500 μL of blocking buffer (purchased from Bio-Tech, catalog number: P0220) and shake at room temperature for 45 min;
[0140] 8) The blocked optical signal enhancing nanoparticle solution was centrifuged for 15 min and the supernatant was discarded;
[0141] 9) Add 500 μL of cleaning solution, vortex to mix, centrifuge for 15 min, and discard the supernatant;
[0142] 10) Add 500 μL of optical signal enhancement nanoparticle storage solution (10 mM PBS containing 0.1% BSA and 0.1% TW20, pH = 7.4), vortex to mix, centrifuge for 15 min, and discard the supernatant;
[0143] 11) Add 500 μL of optical signal enhancement nanoparticle storage solution, vortex to mix, and store at 2-8°C.
[0144] 3. Single molecule immune response detection:
[0145] 1) Preparation of test samples: Use sample diluent (10 mM PBS) to dilute the pTau-181 standard sample to 0 pg / mL, 0.1 pg / mL, 0.5 pg / mL, 1 pg / mL, 5 pg / mL, 10 pg / mL, and 50 pg / mL;
[0146] 2) Take 100 μL of the sample to be tested, add 1 μL of 1.6 mg / mL magnetic bead antibody complex, mix and shake at room temperature for 30 min;
[0147] 3) After the reaction, wash and add 30 μL of optical signal enhancement nanoparticle detection antibody complex, mix and shake at room temperature for 60 min;
[0148] 4) Finally, the immune complex was washed, resuspended in 10 μL of detection solution (10 mM PBS containing 0.1% TW20, pH=7.4), and passed into a droplet generation chip device (purchased from Zhongxin Qiheng, ZX-LD-100Y) to generate droplets encapsulating magnetic beads. The complex was detected under an optical imaging device, Leica DMi8 fluorescence microscope, to obtain a fluorescent image, which was processed and analyzed to obtain the experimental results.
[0149] 4. Experimental Results
[0150] The results showed that the linear range of the p-Tau 181 test of the present invention was 0-50 pg / mL, the lower limit of detection was 0.1 pg / mL, and its R 2 = 0.9971, which meets the requirements. The fluorescence results are as follows Figure 3 As shown, the line graph is Figure 4 shown.
[0151] Comparative Example 1: IL-6 single molecule immune response detection (without droplet dispersion method)
[0152] 1. Magnetic beads modified with antibodies:
[0153] 1) Take 16.7 μL of 30 mg / mL Dynabeads M-270 carboxylic acid magnetic beads (Thermo M270) and place them in a 2 mL centrifuge tube. Mix well and place on a magnetic separator for 1 min. Discard the supernatant.
[0154] 2) Add 300 μL of magnetic bead diluent (10 mM PBS containing 0.1% TW20, pH=7.4), vortex to mix, place on a magnetic separator for 1 min, discard the supernatant, and repeat the above washing operation 3 times;
[0155] 3) Add 300 μL magnetic bead coupling buffer (50 mM MES, pH 5.0), vortex to mix, place on a magnetic separator for 1 min, and discard the supernatant;
[0156] 4) Add 291 μL of magnetic bead coupling buffer, vortex to mix, then add 9 μL of 10 mg / mL EDC, vortex to mix, and shake at 2-8°C for 30 min;
[0157] 5) Place the magnetic bead solution on a magnetic bead separator for 1 min, discard the supernatant, add 300 μL of magnetic bead coupling buffer, vortex to mix, place on a magnetic separator for 15 s, and discard the supernatant;
[0158] 6) Quickly add 300 μL IL-6 capture antibody (Abcam Anti-IL-6 antibody, ab9324), vortex to mix, and shake at 2-8°C for 2 h;
[0159] 7) Place the magnetic bead solution on a magnetic bead separator for 1 min, discard the supernatant, add 300 μL of magnetic bead washing solution, vortex to mix, place on a magnetic separator for 1 min, and discard the supernatant;
[0160] 8) Add 300 μL magnetic bead blocking solution (purchased from Bio-Tech, catalog number: P0220), vortex to mix, and shake at room temperature for 45 minutes;
[0161] 9) Place the magnetic bead solution on a magnetic bead separator for 1 min, discard the supernatant, add 300 μL of magnetic bead diluent, vortex to mix, place on a magnetic separator for 1 min, discard the supernatant, and repeat the above washing operation 3 times;
[0162] 10) Add 300 μL of magnetic bead diluent, vortex to mix, place on a magnetic separator for 1 min, and discard the supernatant;
[0163] 11) Add 300 μL magnetic bead storage solution (10 mM PBS containing 0.1% BSA and 0.1% TW20, pH=7.4), vortex to mix, and store at 2-8°C.
[0164] 2. Optical signal enhancement of nanoparticle-modified antibodies:
[0165] 1) Take 100 μL of 1% optical signal enhancing nanoparticles (purchased from Suzhou Weidu Biotechnology, catalog number: FG0300CA) and place them in a centrifuge, centrifuge for 15 min, and discard the supernatant;
[0166] 2) Add 500 μL of washing solution (10 mM PBS containing 0.1% TW20, pH = 7.4), vortex to mix, centrifuge for 15 minutes, discard the supernatant, and repeat the above washing operation 3 times;
[0167] 3) Add 50 μL of 10 mg / mL EDC and 50 μL of 10 mg / mL NHS and shake at room temperature for 30 min;
[0168] 4) The optical signal enhancement nanoparticle solution was centrifuged for 15 min, the supernatant was discarded, 500 μL of coupling buffer (50 mM MES, pH 5.0) was added, vortexed to mix, centrifuged for 15 min, the supernatant was discarded, and the above operation was repeated 3 times;
[0169] 5) Add 500 μL of coupling buffer and vortex to mix. Add 0.1 mg of IL-6 detection antibody (Abcam biotin Anti-IL-6 antibody, ab84251) and shake at room temperature for 2 h;
[0170] 6) Add 500 μL of coupling buffer, vortex to mix, centrifuge for 15 min, and discard the supernatant;
[0171] 7) Add 500 μL of blocking buffer (purchased from Bio-Tech, catalog number: P0220) and shake at room temperature for 45 min;
[0172] 8) The blocked optical signal enhancing nanoparticle solution was centrifuged for 15 min and the supernatant was discarded;
[0173] 9) Add 500 μL of cleaning solution, vortex to mix, centrifuge for 15 min, and discard the supernatant;
[0174] 10) Add 500 μL of optical signal enhancement nanoparticle storage solution (10 mM PBS containing 0.1% BSA and 0.1% TW20, pH = 7.4), vortex to mix, centrifuge for 15 min, and discard the supernatant;
[0175] 11) Add 500 μL of optical signal enhancement nanoparticle storage solution, vortex to mix, and store at 2-8°C.
[0176] 3. Single molecule immune response detection:
[0177] 1) Preparation of test samples: Use sample diluent (10 mM PBS) to dilute the IL-6 standard sample to 0 pg / mL, 0.01 pg / mL, 0.05 pg / mL, 0.1 pg / mL, 0.5 pg / mL, 1 pg / mL, 5 pg / mL, 10 pg / mL, and 50 pg / mL;
[0178] 2) Take 100 μL of the sample to be tested, add 1 μL of 1.6 mg / mL magnetic bead antibody complex, mix and shake at room temperature for 30 min;
[0179] 3) After the reaction, wash and add 50 μL of optical signal enhancement nanoparticle detection antibody complex, mix and shake at room temperature for 30 min;
[0180] 4) Finally, the immune complex was washed, resuspended in 10 μL of detection solution (10 mM PBS containing 0.1% TW20, pH=7.4), transferred to the detection well, and detected under the optical imaging device Leica DMi8 fluorescence microscope to obtain a fluorescent image and process and analyze it to obtain the experimental results.
[0181] 4. Experimental Results
[0182] The results showed that the linear range of the IL-6 test of the present invention was 0-50 pg / mL, and the lower limit of detection was 0.1 pg / mL, which was higher than that of the droplet dispersion method. Figure 5 As shown, the line graph is Figure 6 shown.
[0183] Comparison of data between embodiment and comparative example:
[0184]
[0185] The minimum detection limit is an important indicator for ensuring the sensitivity of immunological detection methods. The lower the value, the higher the sensitivity. Example 1 uses the droplet dispersion method, and the sensitivity can reach 0.01 pg / mL. The sensitivity of the comparative example that does not use the droplet dispersion method is relatively lower.
[0186] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A non-enzymatic single molecule immune reaction detection method, characterized in that: The steps include: Step (1): mixing a sample to be tested with a capture antibody immobilized on a solid phase carrier, incubating, washing, and obtaining a first complex, wherein the capture antibody binds to a first site of a target molecule in the sample; Step (2): mixing the detection antibody, the optical signal enhancing nanoparticles and the first complex described in step (1), incubating, washing, and obtaining a second complex, wherein the detection antibody binds to the second site of the target molecule, and the detection antibody is coupled to the optical signal enhancing nanoparticles; Step (3): Encapsulating the second complex described in step (2) with droplets, dispersing, collecting optical signals, analyzing, and obtaining detection results.
2. The non-enzymatic single molecule immune reaction detection method according to claim 1, characterized in that: The solid phase carrier is modified with a functional group capable of coupling with an antibody.
3. The non-enzymatic single molecule immune reaction detection method according to claim 1 or 2, characterized in that: The solid phase carrier includes one or more of magnetic beads, micrometer-scale microspheres or nanometer-scale microspheres; The particle size of the magnetic beads is 1 to 3 μm.
4. The non-enzymatic single molecule immune reaction detection method according to any one of claims 1 to 3, characterized in that: The target molecule includes one or more of a protein, a polysaccharide, a small molecule with biological activity, or a complex of a small molecule and a protein.
5. The non-enzymatic single molecule immune reaction detection method according to any one of claims 1 to 4, characterized in that: The coupling includes direct coupling or indirect coupling; The direct coupling includes coupling by physical adsorption or coupling by chemical modification; Such indirect coupling includes coupling via a biotin-streptavidin system.
6. The non-enzymatic single molecule immune reaction detection method according to any one of claims 1 to 5, characterized in that: The particle size of the optical signal enhancing nanoparticles is 100 to 300 nm.
7. The non-enzymatic single molecule immune reaction detection method according to any one of claims 1 to 6, characterized in that: The luminescent material of the optical signal enhancement nanoparticles includes one or more of organic fluorescent dyes, quantum dots, fluorescent proteins, rare earth luminescent materials, aggregation-induced luminescent materials or polymer luminescent materials.
8. The non-enzymatic single molecule immune reaction detection method according to any one of claims 1 to 7, characterized in that: The carrier material of the optical signal enhancing nanoparticles includes one or more of polystyrene, silica, dextran, agarose, inorganic metal compounds or polyacrylamide.
9. The non-enzymatic single molecule immune reaction detection method according to any one of claims 1 to 8, characterized in that: The structure of the optical signal enhancing nanoparticles includes one or more of a hollow structure, a porous structure or a core-shell structure.
10. The non-enzymatic single molecule immune reaction detection method according to any one of claims 1 to 9, characterized in that: include: The incubation time in step (1) is 15 to 60 min; and / or The incubation temperature in step (1) is 25°C to 40°C; and / or The incubation time in step (2) is 15 to 60 min; and / or The incubation temperature in step (2) is 25°C to 40°C.
